(Reuters) – Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
